TITLE

Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment

AUTHOR(S)
F. Moriconi; P. Colombatto; B. Coco; P. Ciccorossi; F. Oliveri; D. Flichman; A. M. Maina; R. Sacco; F. Bonino; M. R. Brunetto
PUB. DATE
August 2007
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p341
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives We studied the impact of hepatitis B virus (HBV) polymerase/reverse transcriptase (Pol/Rt) heterogeneity on adefovir rescue therapy in 34 consecutive chronic hepatitis B patients with viral breakthrough during lamivudine monotherapy. Methods The Pol/Rt A–F domains were directly sequenced in all patients at baseline, and 12 and 24 months. Response to therapy was evaluated at 3, 6, 12 and 24 months by quantitative HBV-DNA. Results Primary treatment failures did not occur. At 6 months 24/34 (70.6%) patients had viraemia P = 0.023). At least one of rtA181S and rtT184S substitutions correlated negatively with IVR and CVR (univariate analysis, P = 0.001) and was independently associated with absence of CVR (P = 0.016). Conclusions Lamivudine monotherapy favours the emergence of viral quasispecies that influence the response rate to adefovir rescue therapy independently from baseline viraemia and lower the susceptibility to other nucleos(t)ide analogues.
ACCESSION #
25856688

 

Related Articles

  • A meta-analysis of the association between IL28B polymorphisms and infection susceptibility of hepatitis B virus in Asian population. Jing Chen; Wei Wang; Xiaoguang Li; Jie Xu // BMC Gastroenterology;Jul2015, Vol. 15 Issue 1, p1 

    Background: Several association studies with small sample sizes of two SNPs in IL28BB (rs12979860 and rs8099917) showed inconsistent results, so in this study, we aim to evaluate the association between the two SNPs and infection susceptibility of Hepatitis B Virus (HBV) in Asian population,...

  • Fine mapping analysis of HLA- DP/DQ gene clusters on chromosome 6 reveals multiple susceptibility loci for HBV infection. Tao, Jingjing; Su, Kunkai; Yu, Chengbo; Liu, Xiaoli; Wu, Wei; Xu, Wei; Jiang, Bingxun; Luo, Rui; Yao, Jian; Zhou, Jiawei; Zhan, Yan; Ye, Chao; Yuan, Wenji; Jiang, Xianzhong; Cui, Wenyan; Li, Ming; Li, Lianjuan // Amino Acids;Dec2015, Vol. 47 Issue 12, p2623 

    Recent genome-wide association studies have revealed the HLA region on chromosome 6p21 as a susceptibility locus for hepatitis B virus (HBV) infection, a finding subsequently replicated in independent samples. However, only limited single nucleotide polymorphisms (SNPs) were analyzed in most of...

  • Leukocyte Telomere Length-Related rs621559 and rs398652 Genetic Variants Influence Risk of HBV-Related Hepatocellular Carcinoma. Pan, Wenting; Cheng, Guangxia; Xing, Huaixin; Shi, Juan; Lu, Chao; Wei, Jinyu; Li, Lichao; Zhou, Changchun; Yuan, Qipeng; Zhou, Liqing; Yang, Ming // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Recent genome-wide association studies (GWAS) have identified eleven leukocyte telomere length (LTL)-related single nucleotide polymorphisms (SNPs). Since LTL has been associated with risk of many malignancies, LTL-related SNPs may contribute to cancer susceptibility. To test this hypothesis in...

  • Nucleoside Analogs as Anti-HBV Agents. Xiao-Xiong Zhou; Littler, Eddy // Current Topics in Medicinal Chemistry;May2006, Vol. 6 Issue 9, p851 

    Chronic hepatitis B virus (HBV) infection affects about 400 million people worldwide. The development of nucleoside analogs that inhibit HBV polymerase provides an important approach for treating HBV infection. The approval of lamivudine, adefovir and entecavir represents a cornerstone of...

  • Replication of Genome Wide Association Studies on Hepatocellular Carcinoma Susceptibility Loci in a Chinese Population. Chen, Kangmei; Shi, Weimei; Xin, Zhenhui; Wang, Huifen; Zhu, Xilin; Wu, Xiaopan; Li, Zhuo; Li, Hui; Liu, Ying // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background: Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA,...

  • Hepatitis B virus genotypes in Mongols and Australian Aborigines. Alestig, E.; Hannoun, C.; Horal, P.; Lindh, M. // Archives of Virology;Dec2001, Vol. 146 Issue 12, p2321 

    Summary. Hepatitis B virus (HBV) is spread worldwide. Seven genotypes, A-G, have been described, differing by more than 8% of the genome. In eastern Asia and Oceania genotypes B and C are predominant. However, little is known about genotypes in Mongolia and Australian aborigines. We analysed the...

  • Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B.  // Clinical Infectious Diseases;3/15/2003, Vol. 36 Issue 6, p687 

    YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4...

  • Molecular Therapeutics of HBV. Ruian Xu; Kexia Cai; Dexian Zheng; Hong Ma; Sue Xu; Sheung-tat Fan // Current Gene Therapy;Aug2003, Vol. 3 Issue 4, p341 

    The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a...

  • Comparison of 12-Month Courses of Interferon-α -2b--Lamivudine Combination Therapy and Interferon-α -2b Monotherapy among Patients with Untreated Chronic Hepatitis B. Yalcin, Kendal; Degertekin, Halil; Yildiz, Fetin; Celik, Yusuf // Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1516 

    We compared the use of prolonged synchronous combination therapy with interferon (IFN)-α-2b and lami-vudine with the use of IFN-α-2b monotherapy in patients with untreated hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection. Thirty-three patients received...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics